Drug intelligence / Profile preview

AD-117A

Development stage: Unknown
Lead developer: Addpharma
Administration: Oral

Overview

AD-117A is an investigational pharmaceutical agent being studied in a crossover clinical trial to compare its pharmacokinetic characteristics and safety profile with AD-117 in healthy adult participants. The primary purpose of the study is to assess plasma drug concentration (Cmax) and area under the plasma concentration-time curve (AUCt). The drug is under development for the treatment of mixed dyslipidemia. Mechanistic, structural, and modality details remain undisclosed in public records. The trial is sponsored by Addpharma.

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)Pol II (RNA polymerase II elongation factors)

Beyond the preview

Go deeper on AD-117A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-117A.

Explore the full profile